Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.

Borson-Chazot F, Dantony E, Illouz F, Lopez J, Niccoli P, Wassermann J, Do Cao C, Leboulleux S, Klein M, Tabarin A, Eberle MC, Benisvy D, de la Fouchardière C, Bournaud C, Lasolle H, Delahaye A, Rabilloud M, Lapras V, Decaussin-Petrucci M, Schlumberger M.

Thyroid. 2018 Sep;28(9):1174-1179. doi: 10.1089/thy.2017.0663.

PMID:
30105951
2.

Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations.

Pujol P, Vande Perre P, Faivre L, Sanlaville D, Corsini C, Baertschi B, Anahory M, Vaur D, Olschwang S, Soufir N, Bastide N, Amar S, Vintraud M, Ingster O, Richard S, Le Coz P, Spano JP, Caron O, Hammel P, Luporsi E, Toledano A, Rebillard X, Cambon-Thomsen A, Putois O, Rey JM, Hervé C, Zorn C, Baudry K, Galibert V, Gligorov J, Azria D, Bressac-de Paillerets B, Burnichon N, Spielmann M, Zarca D, Coupier I, Cussenot O, Gimenez-Roqueplo AP, Giraud S, Lapointe AS, Niccoli P, Raingeard I, Le Bidan M, Frebourg T, Rafii A, Geneviève D.

Eur J Hum Genet. 2018 Dec;26(12):1732-1742. doi: 10.1038/s41431-018-0224-1. Epub 2018 Aug 8.

PMID:
30089825
3.

Functioning Mediastinal Paraganglioma Associated with a Germline Mutation of von Hippel-Lindau Gene.

Bahougne T, Romanet P, Mohamed A, Caselles K, Cuny T, Barlier A, Niccoli P.

J Clin Med. 2018 May 23;7(6). pii: E116. doi: 10.3390/jcm7060116.

4.

Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.

Pellat A, Dreyer C, Couffignal C, Walter T, Lombard-Bohas C, Niccoli P, Seitz JF, Hentic O, André T, Coriat R, Faivre S, Zappa M, Ruszniewski P, Pote N, Couvelard A, Raymond E.

Neuroendocrinology. 2018;107(1):24-31. doi: 10.1159/000487237. Epub 2018 Mar 8.

PMID:
29518779
5.

An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value.

Andriantsoa M, Hoibian S, Autret A, Gilabert M, Sarran A, Niccoli P, Raoul JL.

PLoS One. 2017 May 31;12(5):e0177971. doi: 10.1371/journal.pone.0177971. eCollection 2017.

6.

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.

Walter T, Tougeron D, Baudin E, Le Malicot K, Lecomte T, Malka D, Hentic O, Manfredi S, Bonnet I, Guimbaud R, Coriat R, Lepère C, Desauw C, Thirot-Bidault A, Dahan L, Roquin G, Aparicio T, Legoux JL, Lombard-Bohas C, Scoazec JY, Lepage C, Cadiot G; CEPD investigators.

Eur J Cancer. 2017 Jul;79:158-165. doi: 10.1016/j.ejca.2017.04.009. Epub 2017 May 11.

PMID:
28501762
7.

Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?

Mohamed A, Romano D, Saveanu A, Roche C, Albertelli M, Barbieri F, Brue T, Niccoli P, Delpero JR, Garcia S, Ferone D, Florio T, Moutardier V, Poizat F, Barlier A, Gerard C.

Oncotarget. 2017 Jun 20;8(25):41044-41063. doi: 10.18632/oncotarget.17008.

8.

Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines.

Triponez F, Sadowski SM, Pattou F, Cardot-Bauters C, Mirallié E, Le Bras M, Sebag F, Niccoli P, Deguelte S, Cadiot G, Poncet G, Lifante JC, Borson-Chazot F, Chaffanjon P, Chabre O, Menegaux F, Baudin E, Ruszniewski P, Du Boullay H, Goudet P.

Ann Surg. 2018 Jul;268(1):158-164. doi: 10.1097/SLA.0000000000002191.

9.

Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).

Roquin G, Baudin E, Lombard-Bohas C, Cadiot G, Dominguez S, Guimbaud R, Niccoli P, Legoux JL, Mitry E, Rohmer V, Ruszniewski P, Walter T, Ducreux M, Couvelard A, Scoazec JY, Ramond-Roquin A, Caroli-Bosc FX, Hentic O.

Neuroendocrinology. 2018;106(1):38-46. doi: 10.1159/000457955. Epub 2017 Feb 3.

10.

Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer.

Faure M, Niccoli P, Autret A, Cavaglione G, Mineur L, Raoul JL.

Mol Clin Oncol. 2017 Jan;6(1):44-48. doi: 10.3892/mco.2016.1097. Epub 2016 Dec 1.

11.

Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.

Ruszniewski P, Valle JW, Lombard-Bohas C, Cuthbertson DJ, Perros P, Holubec L, Delle Fave G, Smith D, Niccoli P, Maisonobe P, Atlan P, Caplin ME; SYMNET study group.

Dig Liver Dis. 2016 May;48(5):552-558. doi: 10.1016/j.dld.2015.12.013. Epub 2016 Jan 15.

12.

The value of a rapid contrast-enhanced angio-MRI protocol in the detection of head and neck paragangliomas in SDHx mutations carriers: a retrospective study on behalf of the PGL.EVA investigators.

Gravel G, Niccoli P, Rohmer V, Moulin G, Borson-Chazot F, Rousset P, Pasco-Papon A, Marcus C, Dubrulle F, Gouya H, Bidault F, Dupas B, Gabrillargues J, Caumont-Prim A, Hernigou A, Gimenez-Roqueplo AP, Halimi P.

Eur Radiol. 2016 Jun;26(6):1696-704. doi: 10.1007/s00330-015-4024-5. Epub 2015 Oct 1.

PMID:
26427697
13.

[Neuroendocrine well-differentiated pancreatic tumors].

Niccoli P.

Rev Prat. 2015 Apr;65(4):461-5. French.

PMID:
26058180
14.

Solid pancreatic tumors in patients younger than 40 years old--experience of a French comprehensive cancer center.

Gilabert M, Turrini O, Niccoli P, Moureau-Zabotto L, Boher JM, Poizat F, Giovannini M, Delpero JR, Raoul JL.

Pancreas. 2015 Mar;44(2):345-6. doi: 10.1097/MPA.0000000000000221. No abstract available.

PMID:
25675423
15.

Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.

Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, Niccoli P, Bardet S, Schneegans O, Zanetta S, Schvartz C, Drui D, Chauffert B, Rohmer V, Schlumberger M.

Thyroid. 2015 Apr;25(4):386-91. doi: 10.1089/thy.2014.0361. Epub 2015 Feb 18.

PMID:
25627619
16.

Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'étude des Tumeurs Endocrines (GTE) retrospective study.

Vezzosi D, Cardot-Bauters C, Bouscaren N, Lebras M, Bertholon-Grégoire M, Niccoli P, Levy-Bohbot N, Groussin L, Bouchard P, Tabarin A, Chanson P, Lecomte P, Guilhem I, Carrere N, Mirallié E, Pattou F, Peix JL, Goere D, Borson-Chazot F, Caron P, Bongard V, Carnaille B, Goudet P, Baudin E.

Eur J Endocrinol. 2015 Mar;172(3):309-19. doi: 10.1530/EJE-14-0878. Epub 2014 Dec 23.

PMID:
25538206
17.

Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.

Mohamed A, Blanchard MP, Albertelli M, Barbieri F, Brue T, Niccoli P, Delpero JR, Monges G, Garcia S, Ferone D, Florio T, Enjalbert A, Moutardier V, Schonbrunn A, Gerard C, Barlier A, Saveanu A.

Endocr Relat Cancer. 2014 Oct;21(5):691-704. doi: 10.1530/ERC-14-0086. Epub 2014 Jul 10.

PMID:
25012983
18.

[Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].

Lombard-Bohas C, Cariou B, Vergès B, Coriat R, N'guyen T, François E, Hammel P, Niccoli P, Hentic O.

Bull Cancer. 2014 Feb;101(2):175-83. doi: 10.1684/bdc.2014.1887. Review. French.

PMID:
24557872
19.

Is thyroid cancer recurrence risk increased after transplantation?

Tisset H, Kamar N, Faugeron I, Roy P, Pouteil-Noble C, Klein M, Mourad G, Drui D, Do Cao C, Leenhardt L, Allix I, Bonichon F, Morelon E, Leboulleux S, Kelly A, Niccoli P, Toubert ME, Frimat L, Vantyghem MC, Bournaud C, Schlumberger M, Borson-Chazot F; TUTHYREF network.

J Clin Endocrinol Metab. 2013 Oct;98(10):3981-8. doi: 10.1210/jc.2013-1357. Epub 2013 Jul 24.

PMID:
23884779
20.

One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma.

Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, de la Fouchardiere C, Libé R, Do Cao C, Niccoli P, Tabarin A, Raingeard I, Chougnet C, Giraud S, Gimenez-Roqueplo AP, Young J, Borson-Chazot F, Bertherat J, Wemeau JL, Bertagna X, Plouin PF, Schlumberger M, Baudin E; French group of Endocrine and Adrenal tumors (Groupe des Tumeurs Endocrines-REseau NAtional des Tumeurs ENdocrines and COrtico-MEdullo Tumeurs Endocrines networks).

J Clin Endocrinol Metab. 2013 Oct;98(10):4006-12. doi: 10.1210/jc.2013-1907. Epub 2013 Jul 24.

PMID:
23884775

Supplemental Content

Loading ...
Support Center